IDH1 R132C
|
Cholangiocarcinoma
|
IDH1 R132C
|
Cholangiocarcinoma
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
IDH1 R132C
|
NSCLC
|
IDH1 R132C
|
NSCLC
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
IDH1 R132C
|
Cholangiocarcinoma
|
IDH1 R132C
|
Cholangiocarcinoma
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
IDH1 R132C
|
AML
|
IDH1 R132C
|
AML
|
GSK321 Sensitive: D – Preclinical
|
GSK321 Sensitive: D – Preclinical
|